ABIONYX Pharma SA (EPA:ABNX)

France flag France · Delayed Price · Currency is EUR
3.370
-0.030 (-0.88%)
Mar 2, 2026, 5:35 PM CET
159.23%
Market Cap 119.95M
Revenue (ttm) 4.33M
Net Income (ttm) -4.60M
Shares Out 35.28M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 104,146
Average Volume 119,036
Open 3.220
Previous Close 3.400
Day's Range 3.160 - 3.390
52-Week Range 1.086 - 5.290
Beta 0.88
RSI 39.93
Earnings Date Mar 12, 2026

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 51
Stock Exchange Euronext Paris
Ticker Symbol ABNX
Full Company Profile

Financial Performance

In 2024, ABIONYX Pharma's revenue was 4.55 million, a decrease of -1.92% compared to the previous year's 4.64 million. Losses were -4.38 million, 24.5% more than in 2023.

Financial Statements

News

There is no news available yet.